We’re going to take a little liberty here today, and instead of using this spot to talk about something outside IBJ, we’re going to use it to celebrate the staff in the newsroom.
BE-101, soon to be known as Optavant, is expected to be commercially available in the third quarter of this year after it receives full licensure from the U.S. Department of Agriculture.
Eli Lilly and Co. this month unveiled startling new data for an experimental weight-loss drug. The breakthrough also is prompting some doctors to urge caution.
The Indianapolis drugmaker is purchasing Curevo Inc., LimmaTech Biologics AG and Vaccine Co. Inc. to expand its research and development efforts in infectious disease.
Deal after deal, Eli Lilly and Co. is using the fruits of its success from developing blockbuster GLP-1 medicines to prepare for its next chapter and build a bridge over a looming patent cliff.
President Mung Chiang’s decision to move to Northwestern University comes at an unusually consequential moment for higher education, which is being redefined economically, politically and technologically.
The name BioHeartland was created to give Indiana “a more cohesive and unified way to share the state’s story with investors, companies, researchers and talent around the world,” officials said.
The proposed replacement hospital would cost about $1.64 billion, but the appropriations legislation — the first for the 2027 fiscal year to clear a major congressional hurdle — allows for up to $1.98 billion to go toward the project.
Nearly one-fifth of Indiana’s economic output comes from businesses owned by people over the age of 55, according to a recent analysis from the Indiana Business Research Center.
There’s no doubt the company has been among Indiana’s greatest innovators, employing tens of thousands of Hoosiers and contributing significantly to our state’s economy.
